labcorp america lh
investor day multipl pathway growth
bottom line lh call long term msd consolid revenu growth
compris hsd growth within covanc market lsd
growth core clinic lab includ acquisit bp
walk away increment posit valu prop transform
covanc acquisit diversif effort appar
ever entiti lend complementari servic
cdx data asset fuel lt market share gain respect
ancillari industri rais ep
greater convict reinvigor covanc tp move
risk includ shift demand integr miscu
growth help
mitig core clinic
differenti cro growth engin lh dedic consider portion
day drug develop busi covanc offer
reimburs challeng initi skeptic regard
abil monet combin offerings/data asset recent book
momentum ttm net-btb suggest cro gain traction
amongst core biopharma custom million win associ
combin offer post-clos look ahead expect covanc
leverag bolster abil apac well best-in-class
proprietari data capabl expedit patient recruit site
select evidenc today news strateg technolog agreement
gsk support market share gain lt horizon
posit increasingli value-bas consumer-centr hc
continuum lh seek navig draconian reimburs
environ view lh well-posit low-cost provid clinic
laboratori servic increasingli consumer-centr outcomes-bas
healthcar landscap supplement expect view greater
health system partnership import multi-billion opportun
support growth forese futur consum innov
walgreen partnership progress well patient new
lh vs average increment store slate
consumer-centr initi includ launch in-hom mobil
phlebotomi devic check-in out-of-pocket estim
among other help drive consum engag
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
labcorp provid diagnost test inform servic
better fundament perform sentiment could drive upsid
target price blue sky scenario lh
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
lh
labcorp america lh
price feb rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
labcorp america lh
first investor day sinc lh unveil key strategi high-level
prioriti emphas near term expect focu primarili drive profit
growth integr key acquisit chiltern mount sinai paml
optim enterpris margin manag call mid-singl digit growth across
enterpris long term compris high-singl digit growth drug
develop cro low-singl digit growth core clinic laboratori includ
acquisit bp walk away increment posit
manag present valu proposit transform acquisit
covanc among diversif strategi appar ever
entiti lend complementari servic companion diagnost
proprietari data asset expect lt fuel market share gain
clinic laboratori posit post-pama world
follow tumultu impend implement pama serv
substanti overhang lead clinic laboratori lh peer
larg serv transit year particularli lh seek navig
reduc medicar reimburs rate expect neg impact price
cms-relat volum lh expect harsh
reimburs environ abat near futur lh laid core secular
theme investor day help drive top-line growth market share gain
long term horizon despit fairli challeng fundament backdrop
detail key clinic laboratori highlight investor day
capit evolv value-bas care consumer-centr model
partner govern privat payer provid importantli patient
view lh benefit ever anticip on-going shift valu outcomes-
base care low cost provid lh well-equip work alongsid payer
provid better coordin qualiti care patient menu test
servic patient per day compani economi scale help provid
afford care nation popul vs smaller expens lab oper
also allow employ deep bench physician pathologist scientist
genet counselor provid consult servic provid patient
labcorp america lh
oncolog
area
evolv healthcar environ lh well prepar given deep expertis
capabl consum payer continu search holist high
qualiti afford care
lh also highlight mani initi aim provid care directli patient outsid
tradit patient care center improv overal consum experi recent
launch labcorp walgreen site denver co particip patient
new lh meaning higher rel averag new patient compar
patient servic center note lh expect open addit site addit
exist six within walgreen store across countri end
on-going initi administ care outsid confin tradit patient
servic center includ lh upcom launch in-hom mobil phlebotomi devic
continu partnership direct-to-consum genet test
well introduct out-of-pocket cost estim consum prior
deliveri servic expect lh secular focu consumer-centr model
help support lh organ volum growth expect rise
leader companion diagnost precis medicin
date lh support nearli fda approv companion diagnost
current market boast experi ivd medic devic
studi lead partner companion diagnost precis medicin lh
open north carolina facil dedic sole develop manufactur
test commerci companion diagnost assay compani expect
continu capit grow import companion diagnost coincid
evolv standard care innov util assay expand
neurosci rare diseas furthermor previous discuss import
companion diagnost inevit rise value-bas care world assumpt
payer reimburs therapi efficaci
note lh end-to-end companion diagnost solut one
highli differenti rel peer access three main touch point
develop assay clinic trial test via covanc commerci via legaci
lh test via lh diagnost laboratori speak revenu synergi
relat acquisit covanc lh command presenc companion
diagnost also help spur rise new busi award cro segment
companion diagnost associ trial repres roughli million
covanc current backlog fuel associ net order million
substanti increas million via uniqu offer custom
engag lh earlier develop process due covanc servic help
ivd manufactur well pharmaceut sponsor better navig ensu
approv process note lh companion diagnost busi grown rapidli
past three year compound-annual-growth-rate futur growth like acceler near
futur given continu focu pbm payer outcomes-bas reimburs
value-bas care help fuel fee-for-servic set pama new
physician offic lab leverag posit high-qual low-cost lead nation
provid focu tap signific opportun recent help
establish partnership arrang includ acquisit paml mount sinai
one particular case studi partner shore qualiti partner new jersey
span physician util lh intellig popul health
labcorp america lh
tool addit refer laboratori servic help organ better monitor
high-risk patient popul well identifi high-cost out-of-network lab provid
integr sourc data claim ehr popul health
manag tool cours help gener million save
shore area cost save includ redirect test cost-effici
provid away previou high-cost provid well better coordin
prevent care mitig potenti costli acut care episod at-risk patient
center customer-centr model shore partnership lh also help
boost primari care visit double-digit high-risk patient organ
rank percentil term patient satisfact
one exampl amongst mani case studi exampl natur
import role lh evolv healthcar landscap help larg health
system similar shore navig risk respons increasingli util
reduct adjust tax run rate cash tax save
recent enact tax reform support step capit deploy face
continu challeng fundament environ core clinic laboratori
busi area particular focu compani includ reinvest company-
wide infrastructur one-tim bonu employe share repurchas debt pay
 activ although lh specifi level expect
earmark share repurchas manag note recent earn
call compani expect util fair amount free cash flow
guidanc billion fund share buy-back
move forward expect activ continu integr pillar lh lt
strategi view lead consolid highli fragment billion
us laboratori market particularli smaller lab oper struggl compet post-
pama world note acquisit expect contribut roughli clinic
laboratori revenu growth relat potenti acquisit hospit outreach lab
deal flow expect meaning materi latter half
beyond smaller facil realiz magnitud on-going signific headwind
relat implement new reimburs rate said would note
ceo david king previous highlight expect larger acquisit
occur particularli lh seek integr recent acquir chiltern see note
mount sinai paml would also surpris activ also includ
expans lh ancillari cro busi given industri faster grow
profil seemingli sustain secular growth driver
cro focu
lh clinic develop busi covanc clear bright spot focu area
present offer clearer lt pathway help off-set on-going
reimburs headwind core clinic laboratori busi expect
abat time near futur lh grow cro busi includ earli
develop clinic develop central laboratori servic repres
total revenu meaning margin expans opportun via launchpad
initi detail walk away increment optimist
covanc runway growth market share gain increasingli outsourc clinic
develop industri recent momentum evidenc acceler book trend
past four quarter ttm vs ttm
covanc review refer latest quarter covanc revenu
improv reflect full quarter contribut chiltern acquisit
estim msd organ revenu growth healthi recoveri lighter trend within
labcorp america lh
lh cro busi first half year covanc book momentum
continu quarter ttm net btb acceler
impli healthi fundament environ consist qtd channel check
see note would also note backlog convers improv sequenti
turnaround trend
labcorp covanc valu proposit come fruition
initi skeptic first regard covanc abil monet
realiz materi synergi relat lh clinic laboratori servic data asset
recent momentum new busi award would suggest lh/covanc combin
offer gain traction amongst core biopharma custom alongsid lh covanc
differenti competitor larg stem integr proprietari trove
data asset covanc clinic trial manag system fuel better insight
all-import patient recruit effort trial design real world evid amongst
import offer provid background labcorp wealth data asset stem
real-tim stream high-volum direct-to-pati clinic laboratori data
includ estim million patient encount annual across patient servic
center domest importantli laboratori data identifi patient
physician allow level specif accuraci unriv rel data
util cro peer vs claim datawhich also access
conjunct global central laboratori support global clinic trial
process million patient lab record annual combin entiti
book roughli million new busi award specif relat legaci lh
capabl sinc merger-clos roughli million revenu expect convert
figur covanc cumul new busi award relat lh offer
covanc switch book polici
as-contract basi begin
histor win relat lh
patient data may compar
practic data asset also support best-in-class technolog platform
includ follow detail briefli
xceller covanc popular technolog offer xceller clinic trial
manag system integr allow real-tim feed on-going
clinic trial result multipl data sourc
one exampl pharma client leverag covanc xceller tool recruit
patient domest intern util databas client
reduc time trial start rel similar trial industri peer
labcorp america lh
identifi select high-perform investig site analyz
evid increas popular demand xceller lead
pharmaceut compani glaxosmithklin gsk announc feb
sign strateg technolog agreement covanc util xceller
monitor insight clinic data hub solut
pharmacu demo investor day pharmaacu assist pharma custom
design plan execut clinic trial provid global insight allow
endpoint endpoint util amongst physician appropri identifi patient
elig specif clinic trial also use manag studi logist materi
global specimen solut lastli covanc strateg allianc global
specimen solut allow trial sponsor physicians/investig central
laboratori streamlin global specimen track on-going trial
chiltern fill key gap coverag support lt market share gain
lh announc acquisit chiltern last juli largest cro billion
cash ebitda deal bolster legaci covanc geograph footprint
well therapeut expertis capabl optimist regard
chiltern value-add covanc alreadi signific clinic develop oper
particularli given strength current faster-grow end market within cro
industri particular chiltern strong asia franchis employe apac
pro forma ad exposur faster-grow revenu well
oncolog women health medic devic
ophthalmolog remind lh lack asia oper cite reason
lower covanc profit less abil run global trial estim
trial intern compon broader global clinic trial
theme chiltern help better address
mind conjunct covanc alreadi extens servic offer
span earli develop clinic develop central laboratori believ
clear pathway continu market share gain covanc across
increasingli outsourc cro industri recent momentum evidenc acceler
book past four quarter ttm vs ttm note
net chiltern annual revenu contribut nearli million manag expect
legaci covanc grow msd-hsd organ cours return back
normal histor level vs rel tough experi
lh expect realiz million total annual cost save via launchpad
covanc initi alreadi million cost save realiz
increment million addit million cost synergi expect
realiz cours importantli save expect least partial
off-set on-going gross margin pressur clinic lab busi result price
reduct follow implement pama
on-going focus covanc launchpad initi includ process streamlin
improv softwar autom new infrastructur implement
extract cost synergi help covanc profit better in-lin
clinic cro peer though remain rel unclear current industri averag
given on-going implement optic reduc oper
margin well increasingli fewer public stand-alone comparison purpos
labcorp america lh
contract updat updat
continu await potenti updat commerci contract name unitedhealth
current lh-exclus aetna aet current dgx-exclus labcorp
exclusionari contract renew year-end potenti
open contract could pose meaning headwind lh posit
beyond dynam broadli document point compani last
disclos contribut percentag total revenu expect
overal exposur revenu like nomin higher
compani highlight singl custom repres
recent earn call ceo dave king provid updat regard
relationship highlight recent convers parti acceler
sinc start year also note expect new understand
met near term horizon littl commentari regard much
anticip decis today investor day manag also previous discuss
event contract open parti lh expect give littl
way price inher reduc volum contract
view increment busi may put quest exclus aet
relationship risk potenti off-set lh benefit competit landscap
smaller laboratori could mitig headwind quest labcorp
potenti take meaning share quest character relationship
aet strong littl risk in-network contract see note except
exclusionari claus view note quest relationship optum
contract outsourc bill servic necessarili help potenti
contract hurt view open quest access upper
decemb acla american clinic laboratori file lawsuit
us dept hh us district court columbia alleg fail
properli util market-bas laboratori payment system direct origin
intent pama creat recent implement clinic fee schedul clf
success lawsuit would halt on-going implement new fee schedul
well caus draft new methodolog creation futur
reimburs rate importantli accord lh rule could made
mid-year open brief alreadi file acla februari
remind organ acla call halt implement
reform rate cut better reflect higher rate paid physician hospit
outreach lab account cohort use calcul new
rate despit repres half medicar clf volum
restat basi reflect account chang relat implement
lh initi guidanc earn releas see note
compani expect core clinic laboratori growth vs previou estimate
includ impact relat implement pama
clf manag also expect organ volum growth rel line
experi quarterli averag across covanc manag expect
report revenu growth primarili driven contribut recent
acquir chiltern estim million impli organ growth msd-hsd in-lin
covanc histor growth rate lh expect consolid report revenu
labcorp america lh
charl martineau pm univers toronto growth contribut adj ep rang
yoy growth encompass estim consensu
labcorp america lh
revenu
earn attribut non-controlling
net incom avail common
revenu
revenu
restat
compani mention price
labcorp america lh outperform tp
